Different Vancomycin Immunoassays Contribute to the Variability in Vancomycin Trough Measurements in Neonates-Reference-Cited by-同舟云学术

Different Vancomycin Immunoassays Contribute to the Variability in Vancomycin Trough Measurements in Neonates

Published:2016 Issue: Volume:2016 Page:1-4
ISSN:2314-6133
Container-title:BioMed Research International
language:en
Short-container-title:BioMed Research International

Author:

Samardzic Janko¹²^ORCID,Smits Anne³⁴,Spriet Isabel⁵,Soldatovic Ivan⁶,Atkinson Andrew²,Bajcetic Milica¹⁷,Van Den Anker John N.²⁸⁹,Allegaert Karel³⁹

Affiliation:

1. Institute of Pharmacology, Clinical Pharmacology and Toxicology, Medical Faculty, University of Belgrade, 11000 Belgrade, Serbia

2. Division of Pediatric Pharmacology and Pharmacometrics, University of Basel Children’s Hospital, 4056 Basel, Switzerland

3. Department of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium

4. Neonatal Intensive Care Unit, University Hospitals Leuven, 3000 Leuven, Belgium

5. Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven and Pharmacy Department, University Hospitals Leuven, 3000 Leuven, Belgium

6. Medical Faculty, University of Belgrade, 11000 Belgrade, Serbia

7. Clinical Pharmacology Unit, University Children’s Hospital, 11000 Belgrade, Serbia

8. Division of Pediatric Clinical Pharmacology, Children’s National Medical Center, Washington, DC 20010, USA

9. Intensive Care and Department of Pediatric Surgery, Erasmus MC Sophia Children’s Hospital, 3000 CB Rotterdam, Netherlands

Abstract

Substantial interassay variability (up to 20%) has been described for vancomycin immunoassays in adults, but the impact of neonatal matrix is difficult to quantify because of blood volume constraints in neonates. However, we provide circumstantial evidence for a similar extent of variability. Using the same vancomycin dosing regimens and confirming similarity in clinical characteristics, vancomycin trough concentrations measured by PETINIA (2011-2012,n=400) were 20% lower and the mean difference was 1.93 mg/L compared to COBAS (2012–2014,n=352) measurements. The impact of vancomycin immunoassays in neonatal matrix was hereby suggested, supporting a switch to more advanced techniques (LC-MS/MS).

Funder

KU Leuven

Publisher

Hindawi Limited

Subject

General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://downloads.hindawi.com/journals/bmri/2016/1974972.pdf

Reference13 articles.

1. Vancomycin

2. Getting the dose of vancomycin right in the neonate

3. Clinical pharmacokinetics of vancomycin in the neonate: a review